Seed projects, posters represent a wide range of labs working on technologies, therapeutic strategies, and fundamental research to advance understanding of age-related neurodegenerative disease.
Coupling engineered bacteria with low-power electronics could be highly effective in diagnosis, treatment of bowel diseases.
PhD student Constantine Tzouanas investigates how interactions between individual cells help determine whether pathogens will defeat their hosts — or vice versa.
The Koch Institute’s Annual Symposium highlights emerging successes and challenges in the advancement of vaccines to prevent and treat cancer.
MIT PhD student Kathrin Kajderowicz is studying how hibernation-like states could pave the way for new hypothermic therapies.
A new approach opens the door to a greater understanding of protein-microbe interactions.
A new technology called RIBOmap can give researchers valuable insight into how protein production in animal and human tissue is altered in disease.
SMART researchers combine rifaximin and clarithromycin to effectively restore the latter drug's efficacy.
MIT researchers characterize gene expression patterns for 22,500 brain vascular cells across 428 donors, revealing insights for Alzheimer’s onset and potential treatments.
Tactile stimulation improved motor performance, reduced phosphorylated tau, preserved neurons and synapses, and reduced DNA damage, a new study shows.
Neurons that form part of a memory circuit are among the first brain cells to show signs of neurodegeneration in Alzheimer’s disease.
Researchers develop new, patient-friendly hydrogel platform for administering lifesaving biologics.
On March 10 the FDA approved Trofinetide, a drug based on the protein IGF-1. The MIT professor's original research showing that IGF-1 could treat Rett was published in 2009.
A new study identifies cells that are the most vulnerable within a brain structure involved in mood and movement.
MLK Visiting Professor tries to “maximize connection time” while studying protein evolution.